Coadministration of Nefazodone and Benzodiazepine in the Early Phase of Treatment of Depression.
- Author:
Il Seon SHIN
1
;
Jin Sang YOON
;
Hyeon Joon JEONG
;
Jeong Gil LEE
;
Hyung Yung LEE
Author Information
1. Department of Neuropsychiatry & Research Institute of Medical Science, Chonnam National University Medical School, Kwangju, Korea. jsyoon@chonnam.ac.kr
- Publication Type:Clinical Trial ; Multicenter Study ; Review
- Keywords:
Nefazodone;
Benzodiazepine;
Coadministration;
Depression
- MeSH:
Alprazolam;
Anxiety;
Benzodiazepines*;
Cytochromes;
Depression*;
Glucuronic Acid;
Humans;
Lorazepam;
Outcome Assessment (Health Care);
Sleep Initiation and Maintenance Disorders
- From:Korean Journal of Psychopharmacology
2001;12(3):222-232
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The purpose of this study was to examine the efficacy and safety of coadministration of nefazodone (NEF) and benzodiazepine (BZD) in the clinical setting, particularly during the initial period of treatment. METHODS: This study was based on data collected in an open, multi-center, 8-week, clinical trial of NEF in depressed patients and focused on the first 2 weeks of treatment and the concurrent use of two BZDs: alprazolam (ALP), metabolized largely by the same cytochrome P450-3A4 isoform that metabolizes NEF and lorazepam (LOR), eliminated by conjugation with glucuronic acid and less likely to interact with NEF. Patients receiving NEF alone (NEF-mono group, n=) and those receiving adjunctive BZD therapy (BZD-combi group, n=) were selected and their data were reviewed for demographic and clinical characteristics at baseline and various outcome measures at weeks 1 and 2. The BZD-combi group consisted of patients receiving alprazolam (ALP-combi subgroup, n=) and those receiving lorazepam (LOR-combi subgroup, n=). Efficacy was analysed according to the individual groups and subgroups. In addition, the efficacy at each time point was compared between NEF-mono and BZD-combi groups as well as between ALP-combi and LOR-combi subgroups. Safety and tolerability were judged by reported adverse effects and were compared. RESULTS: In NEF-mono and BZD-combi groups, the mean daily dose for NEF was less than 200 mg/day (range, 50-500 mg/day) and did not differ between groups and subgroups. The mean daily doses for BZDs were 0.61 mg/day (range, 0.25-1.5 mg/day) for ALP and 1.49 mg/day (range, 0.5-2.5 mg/day) for LOR. Sleep, anxiety and depression in both NEF-mono and BZD-combi groups were, in general, significantly improved compared to baseline. Furthermore, BZD-combi group showed greater improvement in anxiety and sleep but not in depression compared to NEF-mono group. Within the BZD-combi group, there was no significant difference in clinical effects between ALP-combi and LOR-combi subgroups. In terms of safety and tolerability, there was no evidence to suggest that BZD combination caused daytime sedation or any other particular adverse events more severely than NEF alone. Also, there was no significant difference in the side effect profiles of ALP-combi and LOR-combi subgroups. CONCLUSION: These results suggest that combining low doses of ALP or LOR with NEF is beneficial for the control of insomnia and anxiety without substantial adverse effects, at least during the early period of treatment of depression when therapeutic dosages of NEF are not yet reached.
